Source
From SEC EDGAR
180 releases originally issued via SEC EDGAR. The issuing organizations are responsible for their content.
MUELLER WATER PRODUCTS REPORTS RECORD FOURTH QUARTER AND FULL YEAR 2026 RESULTS; INTRODUCES FISCAL 2027 GUIDANCE
Achieved Net Sales of $376.5 million in Quarter, $1.5 billion in Fiscal Year
Ascent Industries Reports Third Quarter 2026 Results; Year-Over-Year Net Sales Increase 37.8%, Including 26.3% Growth in Sales Excluding the Midwest Graphic Sales Acquisition; Adjusted EBITDA Improves by $2.1 Million
Sequentially, net sales increased 5.7%, gross profit increased 28.3% and
Aeva Reports Third Quarter 2026 Results
Expanded Product Portfolio in Optical Connectivity with Ultra-High Power Sources and Modules to Address Significant and Growing Demand for AI Data…
Rayonier, L.P.
HOST HOTELS & RESORTS, INC.
Host Hotels & Resorts, Inc. Reports Results for the Third Quarter of 2026
Niagen Bioscience, Inc. Reports Third Quarter 2026 Financial Results
Launched Niagen™ Plus Niagen™ Liquid At-Home Injections
ENACT REPORTS THIRD QUARTER 2026 RESULTS; ANNOUNCES $0.24 QUARTERLY DIVIDEND
_______________________________________
Silvaco Reports Third Quarter 2026 Financial Results
Won major new tier-1 FTCO customer and 4 tier-1 customers for Jivaro Pro in Q3
Amplitude Announces Third Quarter 2026 Financial Results
Annual Recurring Revenue of $431 million, up 24% year-over-year
American Bitcoin Reports Third Quarter 2026 Results
Grows Bitcoin Reserve Through Mining Operations, Increases Satoshis Per Share by Approximately 5%
Rapid7 Announces Third Quarter 2026 Financial Results
•Annualized recurring revenue (“ARR”) of $820 million
LeMaitre Q3 2026 Financial Results
Vaxcyte Reports Third Quarter 2026 Financial Results and Provides Business Update
VAX-31 Adult Indication: Announced Positive Topline Data from OPUS-1 Pivotal Phase 3 Trial; VAX-31 Met All Prespecified Primary Endpoints, Was Well…
Expedia Group Reports Third Quarter 2026 Results
Exceeded guidance with 11% Gross Bookings and 12% revenue growth y/y
ADMA Biologics Reports Third Quarter 2026 Financial Results and Provides Business Update
3Q 2026 Total Revenue of $141.1 Million, Increasing 5% Year-over-Year